Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho Simponi Aria Prior Auth | OpenPaye…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.670

    Simponi Aria (golimumab) for Intravenous Use

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.670 alerts

    Get alerted when Policy MP 5.01.670 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit coverage and prior authorization for intravenous golimumab for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Subcutaneous golimumab is handled under the pharmacy benefit and is outside this policy.

    Policy Summary
    PayerBluecross Idaho
    PolicySimponi Aria (golimumab) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous golimumab before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    Covered indications now include rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis when medical criteria are met.

    The policy added a statement regarding indications in the NCCN Drugs & Biologics Compendium.

    The policy clarified criteria related to tuberculosis infections and tuberculosis screening.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Covered disease indications
    1 yearPrior-approval duration
    2 mg/kgAdult dose basis
    80 mg/m2Pediatric dose basis
    1 mg = 1 unitUnit conversion

    Coverage Criteria

    Initial Therapy

    Simponi Aria (golimumab) intravenous (IV) may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • Golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator (see Appendices).
    • Dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing (see Additional Dosing Information below).
    • ONE of the following covered indications and indication-specific requirements

      • Rheumatoid Arthritis (RA)

        • Individual is 18 years of age or older with moderately to severely active RA.
        • ONE of the following treatment-history pathways

          • ALL of the following

            • Golimumab is used in combination with methotrexate unless there is a contraindication to taking methotrexate or a history of methotrexate intolerance.
            • Individual has had an inadequate response to methotrexate titrated to the maximally tolerated dose.
          • ALL of the following

            • Methotrexate is not tolerated.
            • Individual has had an inadequate response to or is intolerant of other conventional therapy, such as sulfasalazine, leflunomide, or hydroxychloroquine.
          • Individual has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
      • Ankylosing Spondylitis (AS)

        • Individual is 18 years of age or older with active moderate to severe ankylosing spondylitis.
        • Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as NSAIDs or nonbiologic disease-modifying antirheumatic drugs (DMARDs), such as sulfasalazine (see Appendices).
      • Psoriatic Arthritis (PsA)

        • Individual is 2 years of age or older with active moderate to severe psoriatic arthritis.
        • Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, including DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide (see Appendices).
      • Polyarticular Juvenile Idiopathic Arthritis (pJIA)

        • Individual is 2 years of age or older with active moderate to severe polyarticular juvenile idiopathic arthritis.
        • Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, including DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide (see Appendices).

    Continuation Therapy

    Continuation requests for intravenous (IV) golimumab may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • Coverage criteria for initiation of golimumab therapy for the requested indication have previously been met.
    • There is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease.
    • Golimumab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator (see Appendices).

    Investigational or Otherwise Noncovered Use

    Intravenous golimumab may be considered investigational for ALL of the following conditions:

    ALL of the following

    • The criteria for initial or continuation therapy above are not met.
    • The requested use is for an indication other than an oncologic indication. Oncologic requests, including immune checkpoint inhibitor therapy-related toxicities, are evaluated according to National Comprehensive Cancer Network (NCCN) guidelines.

    Subcutaneous golimumab is filled under the pharmacy benefit and is subject to associated utilization management requirements and/or formulary coverage designations, such as prior authorization or formulary coverage restrictions, under the pharmacy benefit. Subcutaneous golimumab is outside the scope of this medical policy.

    Golimumab must NOT be used concurrently with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator (see Appendices).

    Medical Benefit Coding

    HCPCSHCPCS
    J1602Injection, golimumab, 1 mg, for intravenous use only
    CPTCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96366Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96367Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96368Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    NDCNDC
    57894-0350-01Simponi Aria 50 mg/4mL injection, single-dose vial
    ICD-10 Diagnosis CodesICD-10
    M05.00-M06.9Rheumatoid Arthritis (RA)
    M08.00-M08.99Juvenile Idiopathic Arthritis (pJIA)
    L40.50-L40.59Psoriatic Arthritis (PsA)
    M45.0-M45.9Ankylosing Spondylitis (AS)

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for golimumab to support safe, clinically appropriate, and cost-effective use while maintaining optimal therapeutic outcomes.

    Step Therapy

    Rheumatoid Arthritis Conventional-Therapy Step

    For rheumatoid arthritis, document that the individual is receiving golimumab with methotrexate unless methotrexate is contraindicated or not tolerated, and has had an inadequate response to methotrexate titrated to the maximally tolerated dose. If methotrexate is not tolerated, document inadequate response to or intolerance of sulfasalazine, leflunomide, or hydroxychloroquine; alternatively, document contraindications to all four conventional therapies.

    • Individual must be at least 18 years old with moderately to severely active rheumatoid arthritis.

    Drug Background

    Golimumab is a human monoclonal antibody that binds soluble and transmembrane tumor necrosis factor alpha (TNF-alpha), inhibiting TNF-mediated inflammatory activity. Elevated TNF-alpha contributes to chronic inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

    Safety Considerations

    TNF inhibitor safety warning
    Serious infectionsTNF inhibitors, including golimumab, increase the risk of serious infections that may lead to hospitalization or death.
    Infection managementDiscontinue TNF inhibitor therapy if the individual develops a serious infection or sepsis.
    Tuberculosis screeningTest for latent tuberculosis before TNF-inhibitor use and during therapy; initiate treatment for latent tuberculosis before use.
    Malignancy riskLymphoma and other malignancies have been reported in children and adolescents treated with TNF inhibitors; postmarketing cases of hepatosplenic T-cell lymphoma have also been reported.
    Risk assessmentCarefully consider the risks and benefits before initiating therapy in individuals with chronic or recurrent infection.

    Initial Intravenous Golimumab Therapy

    Initial Intravenous Golimumab Therapy

    Initial intravenous golimumab therapy may be considered medically necessary when all general requirements and one covered indication-specific pathway are satisfied.

    General initial-treatment requirements and one covered indication

    • No prohibited combination: Golimumab is not used in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.
    • Dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.
    • ONE indication-specific pathway

      • Rheumatoid arthritis

        • The individual is 18 years of age or older with moderately to severely active rheumatoid arthritis.

    Continuation of Intravenous Golimumab

    Continuation of Intravenous Golimumab

    Continuation requests for intravenous golimumab may be considered medically necessary when all criteria are met.

    Continuation criteria

    • Coverage criteria for initiation of golimumab therapy for the requested indication were previously met.
    • There is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease.
    • Golimumab is not used in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Required Conventional Therapy

    StepTherapy requirementException or alternative
    1Use methotrexate in combination with golimumab and demonstrate an inadequate response to methotrexate titrated to the maximally tolerated dose.If methotrexate is contraindicated or not tolerated, demonstrate an inadequate response to or intolerance of sulfasalazine, leflunomide, or hydroxychloroquine. A contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine also satisfies the conventional-therapy requirement.

    Dosing and Quantity Parameters

    Adult dosing
    Covered adult indicationsRheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Loading dose2 mg/kg at weeks 0 and 4.
    Maintenance dose2 mg/kg every 8 weeks.
    Pediatric dosing
    Covered pediatric indicationsPolyarticular juvenile idiopathic arthritis or ankylosing spondylitis.
    Loading dose80 mg/m2 at weeks 0 and 4.
    Maintenance dose80 mg/m2 every 8 weeks.

    Covered Sites of Administration

    Billing Rule

    Bill intravenous golimumab under the medical benefit

    Intravenous golimumab is covered under the medical benefit. Use the applicable medical-benefit billing and authorization process for treatment provided in an infusion center.

    Billing Rule

    Outpatient physician office is an applicable place of service

    Outpatient physician office is an identified place of service for medical-benefit coding of intravenous golimumab.

    Billing Rule

    Infusion clinic is an applicable place of service

    Infusion clinic is an identified place of service for medical-benefit coding of intravenous golimumab.

    Policy Summary
    PayerBluecross Idaho
    PolicySimponi Aria (golimumab) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous golimumab before treatment.
    SourceLink
    On This Page
    Coverage CriteriaMedical Benefit CodingProvider Requirements and Action ItemsDrug BackgroundSafety ConsiderationsInitial Intravenous Golimumab TherapyContinuation of Intravenous GolimumabRequired Conventional TherapyDosing and Quantity ParametersCovered Sites of Administration
    Step Therapy

    Conventional-Therapy Step for Other Indications

    For ankylosing spondylitis, psoriatic arthritis, or polyarticular juvenile idiopathic arthritis, document an inadequate response to, intolerance of, or contraindication to the applicable conventional therapy before requesting golimumab.

    • Ankylosing spondylitis: conventional therapy may include NSAIDs or nonbiologic DMARDs such as sulfasalazine.
    • Psoriatic arthritis or polyarticular juvenile idiopathic arthritis: conventional therapy may include DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
    Denial Risk

    Noncovered Combinations, Dosing, or Indications

    Golimumab is not covered when used with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator, or when dosing is not initiated according to FDA-approved labeling or accepted drug-compendia dosing. Continuation requests must meet initiation criteria, demonstrate clinically significant and functionally relevant improvement or stabilization, and avoid prohibited combinations; requests that do not meet these criteria, or are for other non-oncologic indications, may be considered investigational.

    • Do not combine golimumab with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.
    • Use FDA-approved or accepted drug-compendia dosing.
    • Oncologic requests are evaluated under NCCN guidelines and the applicable prior-authorization guidance.
    Billing Rule

    Subcutaneous Golimumab: Pharmacy-Benefit Management

    Subcutaneous golimumab is outside the scope of this medical policy. It must be evaluated under the pharmacy benefit, including any applicable utilization-management requirements or formulary restrictions such as prior authorization.

    • This medical policy addresses intravenous golimumab under the medical benefit.
    Age >=18 years; moderately to severely active RA
  1. Golimumab is used in combination with methotrexate unless there is a contraindication to taking methotrexate or a history of methotrexate intolerance.
  2. Conventional-therapy pathway

    • The individual has had an inadequate response to methotrexate titrated to the maximally tolerated dose.
    • When methotrexate is not tolerated, the individual has had an inadequate response to or is intolerant of sulfasalazine, leflunomide, or hydroxychloroquine.
    • The individual has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
  3. Ankylosing spondylitis

    • The individual is 18 years of age or older with active moderate to severe ankylosing spondylitis.Age >=18 years; active moderate to severe AS
    • The individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as NSAIDs or nonbiologic DMARDs such as sulfasalazine.
  4. Psoriatic arthritis

    • The individual is 2 years of age or older with active moderate to severe psoriatic arthritis.Age >=2 years; active moderate to severe PsA
    • The individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
  5. Polyarticular juvenile idiopathic arthritis

    • The individual is 2 years of age or older with active moderate to severe polyarticular juvenile idiopathic arthritis.Age >=2 years; active moderate to severe pJIA
    • The individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
  6. Simponi Aria solution
    Prior approval duration1 year.
    Dosage formSimponi Aria solution 50 mg/4 mL single-dose vial (50 unit single-dose vial).
    Unit conversion1 mg = 1 unit.
    Billing Rule

    Home health is an applicable place of service

    Home health is an identified place of service for medical-benefit coding of intravenous golimumab.